 |
Astex Pharmaceuticals Reports 2012 Third Quarter Financial Results
Oct 30, 2012
|
31.0 KB |
|
| |
Dacogen Approved in the European Union for the Treatment of Elderly AMLInitiated HSP90 Inhibitor AT13387 Clinical Trials in Prostate & Lung Cancer PatientsInitiated SGI-110 Clinical Trial in Ovarian CancerEnded Quarter With Nearly $130 Million in Cash & Marketable Securities
DUBLIN, Calif., Oct. 30, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceutical...
|
|
Astex Pharmaceuticals, Cancer Research Technology and Newcastle University Sign Strategic Drug Discovery Alliance
Oct 29, 2012
|
27.0 KB |
|
| |
DUBLIN, Calif. and CAMBRIDGE, U.K., Oct. 29, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, Cancer Research Technology Limited (CRT) and Newcastle University have signed a major five-year strategic drug discovery alliance. ...
|
|
Astex Pharmaceuticals Announces Initiation of AT13387 Phase 2 Study in Non-Small Cell Lung Cancer
Oct 24, 2012
|
15.9 KB |
|
| |
DUBLIN, Calif., Oct. 24, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, announced that it has initiated an open label, randomized, controlled, multi-center, Phase 2 clinical trial, evaluating HSP90 inhibitor AT13387 in anap...
|
|
Astex Pharmaceuticals to Announce 2012 Third Quarter Financial Results on October 30, 2012
Oct 23, 2012
|
12.2 KB |
|
| |
DUBLIN, Calif, Oct. 23, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced that it will release its 2012 third quarter financial results on Tuesday, October 30, 2012. James S.J. Manuso, PhD, chairman and chief e...
|
|
Astex Scientists Publish the Discovery of Novel Allosteric Modulators for the Key Therapeutic Targets HCV NS3 and PKM2 in Nature Journals
Oct 15, 2012
|
14.8 KB |
|
| |
DUBLIN, Calif., Oct. 15, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, announced that Astex scientists have published two new articles describing the discovery of novel allosteric modulators for the key therapeutic targets...
|
|
Astex Pharmaceuticals Announces the Appointment of President Harren Jhoti, PhD to the BioIndustry Association Board of Directors
Oct 10, 2012
|
14.9 KB |
|
| |
DUBLIN, Calif., Oct. 10, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, announced that Harren Jhoti, PhD, president and director of Astex Pharmaceuticals, was appointed to the BioIndustry Association (BIA) Board of Director...
|
|
Astex Pharmaceuticals Earns $5 Million for First Commercial Sale of DACOGEN(R) in the European Union
Oct 9, 2012
|
15.1 KB |
|
| |
DUBLIN, Calif., Oct. 9, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, announced that a $5 million dollar milestone was earned from Eisai Inc., for the first commercial sale of DACOGEN® in the European Union.
Dr. J...
|
|
Astex Pharmaceuticals Announces Initiation of SGI-110 Phase 2 Trial in Platinum-Resistant Recurrent Ovarian Cancer Patients
Oct 2, 2012
|
16.1 KB |
|
| |
DUBLIN, Calif., Oct. 2, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, announced that it has initiated a Phase 2, open label, randomized, multi-center, controlled clinical trial, evaluating SGI-110 in combination with carbo...
|
|
Astex Pharmaceuticals to Present at BIO Investor Forum
Oct 2, 2012
|
11.4 KB |
|
| |
DUBLIN, Calif., Oct. 2, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced that James S.J. Manuso, PhD, chairman and chief executive officer, will present at BIO Investor Forum on Tuesday, October 9th in San Fra...
|
|
DACOGEN(R) Approved in the European Union for the Treatment of Acute Myeloid Leukemia
Sep 28, 2012
|
69.0 KB |
|
| |
DUBLIN, Calif., Sept. 28, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, announced that Janssen-Cilag International NV was notified that the European Commission has approved the marketing authorization for DACOGEN® (de...
|
|
Astex Pharmaceuticals Discontinues Amuvatinib Clinical Development Program
Sep 21, 2012
|
13.6 KB |
|
| |
DUBLIN, Calif., Sept. 21, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced that clinical development of amuvatinib (MP-470), a multi-targeted tyrosine kinase inhibitor that inhibits the mutant forms of c-Kit a...
|
|
Astex Pharmaceuticals to Participate on Oncology Panels at Upcoming Investor Conferences
Sep 18, 2012
|
11.9 KB |
|
| |
DUBLIN, Calif., Sept. 18, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced that members of the Astex management team will participate as presenters on oncology panels at two upcoming investor conferences.
...
|
|
Astex Pharmaceuticals Announces Initiation of HSP90 Inhibitor AT13387 Clinical Trial in Prostate Cancer Patients
Sep 10, 2012
|
15.9 KB |
|
| |
DUBLIN, Calif., Sept. 10, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, announced that it has initiated a clinical trial with HSP90 inhibitor AT13387 in prostate cancer patients. The AT13387-04 study is a Phase 1-2, open l...
|
|
Astex Pharmaceuticals, Cancer Research Technology and The Institute of Cancer Research Announce Epigenetic Drug Discovery Collaboration
Sep 6, 2012
|
25.4 KB |
|
| |
DUBLIN, Calif., and CAMBRIDGE, UK, Sept. 6, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, Cancer Research Technology Limited (CRT) and The Institute of Cancer Research, London, have initiated a collaboration to discover an...
|
|
Astex Pharmaceuticals to Participate on Epigenetics Panel at Rodman & Renshaw Conference
Sep 4, 2012
|
11.7 KB |
|
| |
DUBLIN, Calif., Sept. 4, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced that James S.J. Manuso, PhD, chairman and chief executive officer, will participate in a Rodman & Renshaw Global Investment Conference ...
|
|
Astex Pharmaceuticals to Present at September Investor Conferences
Aug 30, 2012
|
12.1 KB |
|
| |
DUBLIN, Calif., Aug. 30, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced that members of its senior management team will present at the following investor conferences in September:
Stifel Nicolaus Hea...
|
|
Astex President Awarded Prous Institute-Overton and Meyer Award for New Technologies in Drug Discovery
Aug 20, 2012
|
13.1 KB |
|
| |
DUBLIN, Calif., Aug. 20, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced that its president and director, Harren Jhoti, PhD, will be presented with the 2012 Prous Institute-Overton and Meyer Award for New Tec...
|
|
Astex Pharmaceuticals Reports 2012 Second Quarter Financial Results
Jul 30, 2012
|
180.8 KB |
|
| |
Dacogen Royalty Revenue Increased 25% From Prior Year$5.4 Million Earned on Phase I Trial Initiation of FGFR Kinase InhibitorDacogen Receives Positive Regulatory Recommendation in the EU for Treatment of Elderly AML
DUBLIN, Calif., July 30, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), today reported financial results for ...
|
|
Astex Pharmaceuticals to Announce 2012 Second Quarter Financial Results on July 30, 2012
Jul 24, 2012
|
12.2 KB |
|
| |
DUBLIN, Calif., July 24, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced that it will release its 2012 second quarter financial results on Monday, July 30, 2012. James S.J. Manuso, PhD, chairman and chief exe...
|
|
DACOGEN(R) Receives a Positive Regulatory Recommendation in the European Union for Treatment of Acute Myeloid Leukemia
Jul 20, 2012
|
16.8 KB |
|
| |
DUBLIN, Calif., July 20, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced that Janssen-Cilag International NV was notified that the Committee for Medical Products for Human Use (CHMP) of the European Medicines...
|
|
|
Delicious
Digg
Facebook
LinkedIn
Twitter